| Biomarker ID | 797 |
| PMID | 22052531 |
| Year | 2011 |
| Biomarker | hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miRNA-141):- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-298):- DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; synapse;Golgi apparatus; positive regulation of gene expression Pathways Include(miRNA- 375):-DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome |
| Experiment | Normal Vs Metastatic Tumor |
| Type of Biomarker | Diagnostic |
| Cohort | 128 primary prostate cancers, 29 non-malignant tissues and 14 metastases were selected for the study. GEO accession number: GSE21036 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p≤ 0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | hsa-mir-141, hsa-mir-298, hsa-mir-346, hsa-mir-375 |